Chromosomal translocations and somatic mutations occurring in the 5 0 noncoding region of the BCL6 gene, encoding a transcriptional repressor, are most frequent genetic abnormalities associated with non-Hodgkin B-cell lymphoma and result in deregulated expression of BCL6. However, the significance of deregulated expression of BCL6 in lymphomagenesis and its effect on clinical outcomes of lymphoma patients have remained elusive. In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated. BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6. BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis. In these lymphoma cell lines, etoposide increased the generation of reactive oxygen species (ROS) and reduced mitochondria membrane potential, both of which were inhibited by the antioxidant N-acetyl-l-cysteine (NAC). NAC also inhibited apoptosis. Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents. These results raise the possibility that deregulated expression of BCL6 may endow lymphoma cells with resistance to chemotherapeutic reagents, most likely by enhancing the antioxidant defense systems.
Introduction
The BCL6 gene was originally identified on the break point of a chromosomal translocation involving 3q27 in diffuse large B-cell lymphoma (DLBCL) (Kerckaert et al., 1993; Ye et al., 1993; Miki et al., 1994) . The BCL6 gene encodes a transcriptional repressor containing a carboxy-terminal DNA-binding zinc-finger domain and an amino-terminal BTB/POZ domain, which can bind to transcriptional repressor cofactors, including N-CoR and SMRT, and, thereby, recruit the histone deacetylase protein complex (reviewed in Dent et al., 2002; Niu, 2002) . BCL6 is preferentially expressed in germinal center B cells and has been demonstrated to be required for the formation of germinal centers (Cattoretti et al., 1995; Onizuka et al., 1995; Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997) . A recent study with DNA microarray analysis revealed that BCL6 represses a discrete set of genes involved in B-cell activation, terminal differentiation, and inflammation (Shaffer et al., 2000) . It has thus been hypothesized that downregulation of BCL6 is required for germinal center B cells to differentiate into plasma cells. Consistent with this hypothesis, BCL6 expression is regulated by signals important for the differentiation of germinal center B cells. For instance, the expression of BCL6 is downregulated at the transcriptional level by the CD40 receptor signaling (Allman et al., 1996) and at the protein level by the B-cell receptor signaling, which induces phosphorylation of Ser333 and Ser343 of BCL6 through activation of Erks and, thereby, targets BCL6 for degradation by the ubiquitin proteasome pathway (Niu et al., 1998) .
Chromosomal translocations involving the BCL6 gene represent the most common genetic abnormality in non-Hodgkin B-cell lymphomas and have been demonstrated in 27-45% of DLBCL and 5-14% of follicular lymphomas (Bastard et al., 1994; Lo Coco et al., 1994; Otsuki et al., 1995; Ohno and Fukuhara, 1997) . These translocations typically juxtapose the intact BCL6-coding sequences with heterologous promoters from genes expressed in B cells, including the immunoglobulin genes, thus causing deregulated expression of BCL6 Chen et al., 1998) . Besides this promoter substitution mechanism, occasional microdeletions and frequent multiple somatic mutations in the 5 0 noncoding negative autoregulatory region of the BCL6 gene have been shown to deregulate the expression of BCL6 in lymphoma cells (Kikuchi et al., 2000; Nakamura, 2000; Wang et al., 2002) . Since the BCL6 gene is most frequently affected in non-Hodgkin B-cell lymphomas, it has been suggested that deregulated expression of BCL6 should play an important role in lymphomagenesis. However, the oncogenic ability of BCL6 in B cells has remained elusive. It has also remained very controversial as to whether the BCL6 gene alterations affect the clinical outcome of patients with Non-Hodgkin lymphomas (reviewed in Lossos et al., 2001; Barrans et al., 2002; Dent et al., 2002; Niu, 2002) .
To gain insight into the significance of deregulated BCL6 expression in the pathogenesis and prognosis of non-Hodgkin lymphomas, we overexpressed BCL6 in germinal center B-cell-derived lymphoma cell lines, Daudi and Raji, and examined the effects on cell proliferation and apoptosis. BCL6 overexpression significantly inhibited apoptosis of lymphoma cells in response to etoposide and other chemotherapeutic reagents. BCL6 overexpression also inhibited the increase in reactive oxygen species (ROS) levels and the reduction of mitochondria transmembrane potential (Dc m ) in response to etoposide. The ROS scavenger Nacetyl-l-cysteine (NAC) also inhibited the reduction of Dc m and apoptosis as well as the increase in ROS levels in etoposide-treated lymphoma cells. These observations indicate that BCL6 overexpression inhibits apoptosis of lymphoma cells treated with chemotherapeutic reagents, most likely through enhancement of the antioxidant defense systems.
Results

BCL6 overexpression inhibits apoptosis of B-cell lymphoma cells treated with etoposide
To explore the possibility that overexpression of BCL6 may have an effect on the proliferation of lymphoma cells or on their responses to chemotherapeutic reagents, we established a clone of the Burkitt's lymphoma Daudi cell line, Daudi/Ton-BCL6, as described under Materials and methods. As shown in Figure 1a , Daudi/Ton-BCL6 cells express a low level of BCL6, comparable with that in parental Daudi cells, in the absence of doxycycline (DOX) and inducibly overexpress BCL6 when cultured in the presence of DOX. We first examined the effect of BCL6 overexpression on cell growth by culturing Daudi/Ton-BCL6 cells in the presence or absence of DOX and by measuring the number of viable cells for up to 4 days by the XTT colorimetric assay, as described under Materials and methods. However, we did not observe any significant effect of BCL6 overexpression on cell proliferation in repeated experiments (negative data not shown).
We next examined the effect of BCL6 overexpression on the response of Daudi cells to etoposide, a topoisomerase II inhibitor commonly used as a chemotherapeutic reagent in the treatment of lymphoma. Daudi/Ton-BCL6 cells were cultured for 24 h with various concentrations of etoposide in the presence or absence of DOX, and the numbers of viable cells were measured by the XTT assay. As shown in Figure 1b , etoposide decreased the number of viable cells in a dosedependent manner in the presence or absence of DOX. However, a significantly higher number of cells survived the treatment of etoposide at concentrations as high as 2 mm when cultured with DOX, which indicates that Daudi cells overexpressing BCL6 are more resistant to etoposide treatment than cells expressing the endogenous level of BCL6.
Chemotherapeutic reagents, including etoposide, have been known to induce apoptosis of cancer cells. Therefore, we next examined the effect of BCL6 overexpression on etoposide-induced apoptosis by the annexin V staining method, as described under Materials and methods. Etoposide induced apoptosis of Daudi/Ton-BCL6 cells in time-and dose-dependent manners (Figure 2 and data not shown). Notably, the fraction of annexin V-positive, apoptotic cells was consistently smaller in the presence as compared with the absence of To rule out the possibility that the anti-apoptotic effect of BCL6 overexpression observed in Daudi cells is unique to this cell line, we also examined Raji cells, another Burkitt's lymphoma cell line. As described under Materials and methods, we established a Raji clone, Raji-BCL6, overexpressing wild-type BCL6, and a clone, Raji-BCL6-Ala333/343, overexpressing the BCL6-Ala333/343 mutant, in which main phosphorylation targets for Erks, Ser333 and Ser343 (Niu et al., 1998) are mutated. As shown in Figure 4 , etoposideinduced apoptosis, as estimated by annexin V binding as well as by cleavage of PARP, was moderately or more remarkably inhibited in Raji-BCL6 or Raji-BCL6-Ala333/343 cells, respectively, as compared with that in parental Raji cells (Figure 4 ). Similar to the observation in Daudi cells, the expression level of BCL6 in parental Raji cells significantly declined after etoposide treatment, while that in Raji-BCL6 cells showed a more moderate decline. On the other hand, the expression level of BCL6-Ala333/343 in Raji-BCL6-Ala333/343 did not show any decline, but transiently increased at 8 h after etoposid treatment in repeated experiments ( Figure 4b and data not shown). Thus, these results have confirmed the antiapoptotic effect of BCL6 overexpression in B-cell lymphoma cells treated with etoposide and revealed that etoposide induces the decline in BCL6 level, which correlated with apoptosis. Furthermore, it was demonstrated that Ser333 and Ser343 are not required for the antiapoptotic effect, but may be involved in etoposide-induced decline in BCL6 level. 
Etoposide induces a proteasome-dependent degradation of BCL6
As the expression level of BCL6 declined rapidly in cells undergoing etoposide-induced apoptosis, we next investigated the mechanism for this decline. First, we examined the effect of the broad spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone (Z-VAD-fmk). As expected, pretreatment with 50 mm Z-VAD-fmk inhibited the cleavage of PARP in Daudi cells treated with etoposide ( Figure 5a ). However, Z-VAD-fmk did not show any inhibitory effect on the etoposide-induced decline in the BCL6 expression level. We next examined the effect of N-CBZ-Leu-Leu-Leu-AL (MG132), a proteasome inhibitor previously shown to inhibit the degradation of BCL6 in germinal center B cells treated with anti-IgM antibody (Niu et al., 1998) .
As shown in Figure 5b and c, pretreatment with MG132 significantly inhibited the decline in the BCL6 expression level in both Daudi and Raji cells treated with etoposide, while MG132 increased or decreased the PARP cleavage induced by etoposide in Daudi or Raji cells, respectively. We also examined the effect of lactacystin, a more specific proteasome inhibitor as compared with MG132, and confirmed its inhibitory effect on etoposide-induced BCL6 degradation in both Daudi and Raji cells (data not shown). These results indicate that BCL6 is rapidly degraded in etoposidetreated cells, not by caspases, but through the proteasome pathway.
BCL6 overexpression represses the etoposide-induced increase in ROS levels and reduction of Dc m
In an attempt to gain insight into the mechanisms by which overexpression of BCL6 confers resistance to etoposide, we next examined whether etoposide enhances the generation of ROS, which have been shown to play important roles in the initiation and execution of apoptosis (reviewed in Fleury et al. (2002) , Jabs (1999) ). As shown in Figure 6a , treatment of Raji cells with 1 mm etoposide for 12-48 h induced a time-dependent increase in ROS levels, as estimated fluorometrically using a fluorescent probe, dihydroethidium (HE). Furthermore, Etoposide ( (Figure 6a ). The etoposide-induced increases in ROS generation in these clones, thus, correlated with their sensitivities to etoposide-induced apoptosis, which raises a possibility that BCL6 overexpression may mitigate etoposideinduced apoptosis by reducing ROS levels. Since mitochondrial membrane permeabilization also plays an important role in the induction of apoptosis (reviewed in Fleury et al. (2002) , Jabs (1999) , Zamzami and Kroemer (2001) To examine the effects of increased levels of ROS on reduction of Dc m and apoptosis in cells treated with etoposide, we pretreated Raji cells with the ROS scavenger NAC and further treated cells with etoposide as well as NAC for 24-48 h. As shown in Figure 7a , NAC partially inhibited the etoposide-induced increase in ROS levels. In addition, NAC also partially reduced the loss of Dc m and apoptosis in Raji cells treated with etoposide (Figure 7b, c) . These results suggest that the etoposide-induced increase in ROS levels may play a role in the induction of the loss of Dc m , thus leading to apoptosis, and support the idea that BCL6 overexpression inhibits apoptosis by reducing ROS levels.
We also examined the correlation between BCL6 overexpression and the etoposide-induced ROS generation in Daudi/Ton-BCL6 cells. Unlike Raji cells, the increase in ROS levels in these cells after etoposide treatment was not observed in whole population of cells, but in some fraction of cells. However, the fraction of cells showing high levels of ROS after treatment with various concentrations with etoposide was significantly reduced when cells were cultured with DOX to overexpress BCL6 (Figure 8) . Therefore, etoposide-induced increase in ROS levels correlated with sensitivity to etoposide-induced apoptosis, which is in accordance with the idea that BCL6 overexpression inhibits apoptosis by reducing ROS levels.
BCL6 overexpression prevents the increase in ROS levels and apoptosis in cells treated with various chemotherapeutic reagents
To examine whether the antiapoptotic effect of BCL6 overexpression is specific for the topoisomerase II inhibitor etoposide, we examined three other chemotherapeutic reagents that are in common use for (Chabner and Longo, 2001) . Daunorubicin also inhibits topoisomerase II to induce DNA strand breakage as well as intercalates between DNA base pairs. Ara-C is phosphorylated to Ara-CTP, competes with dCTP for incorporation into newly synthesized DNA, and terminates DNA chain elongation. Vincristine inhibits tubulin polymerization and prevents the formation of mitotic spindle (Chabner & Longo, 2001) . In spite of different mechanisms of action for these reagents, induction of BCL6 overexpression by DOX treatment in Daudi/Ton-BCL6 cells reduced apoptosis induced by each of these three reagents, as estimated by annexin V binding as well as by cleavage of PARP (Figure 9a and data not shown). Similarly, Raji clones overexpressing BCL6 or the BCL6-Ala333/343 mutant exhibited resistance to each of these reagents as compared with parental cells (data not shown).
Furthermore, treatment of Daudi/Ton-BCL6 cells with daunorubicin, Ara-C, or vincristine increased the ROS levels, which was reduced by overexpression of BCL6 induced by DOX (Figure 9b ). On the other hand, DOX did not have any effect on the increase in ROS levels and apoptosis in Daudi/Ton cells treated with these chemotherapeutic reagents (data not shown). These results indicate that overexpression of BCL6 endows resistance to various chemotherapeutic reagents most likely by reducing the ROS generation.
Discussion
In the present study, we inducibly or constitutively overexpressed BCL6 in germinal center B-cell-derived lymphoma cells, Daudi or Raji cell lines, respectively, and examined the effects of BCL6 overexpression on cell proliferation and apoptosis. In both cell lines, BCL6 overexpression neither affected cell proliferation nor induced apoptosis. However, apoptosis induced by various chemotherapeutic reagents were partially but significantly prevented by BCL6 overexpression in both cell lines, as examined by the annexin V binding assay. Further studies in detail on etoposide-treated cells Antiapoptotic effect of BCL6 in lymphoma cells T Kurosu et al revealed that BCL6 overexpression has inhibitory effects on decrease in Dc m generation of ROS, and caspasemediated cleavage of PARP in these cells. Intriguingly, BCL6 was found to undergo a proteasome-dependent degradation in etoposide-treated cells. These findings strongly suggest that the deregulated BCL6 expression in B-cell lymphomas plays a role in the modulation of apoptotic responses of these cells to chemotherapeutic reagents and, thus, may have a significant effect on clinical outcomes of lymphoma patients treated with chemotherapy. In contrast to these results, Yamochi et al. (1999) previously reported that adenovirus-mediated overexpression of BCL6 in CV-1 and HeLa cells induced cell cycle arrest at the G2/M phase and apoptosis. Similarly, Albagli et al. (1999) reported that tetracycline-regulated overexpression of BCL6 in U2OS osteosarcoma cells impaired S phase progression and apoptosis. It should be noted, however, that the cell lines utilized in these studies are nonlymphoid cells, which do not normally express BCL6. Thus, it is speculated that the effects of BCL6 overexpression in nonlymphoid cells that do not normally express BCL6 are quite different from those in lymphoma cells of germinal center B-cell origin. Yamochi et al. (1999) also reported that apoptosis induced by BCL6 overexpression in CV-1 and HeLa cells was preceded by downregulation of apoptosis repressors BCL2 and BCL-X L . In accordance with this, Tang et al. (2002) recently reported that the forced expression of a constitutively active mutant of AFX, a member of the forkhead family of transcription factors, in HeLa cells induced apoptosis as well as overexpression of BCL6 and downregulation of BCL-X L . BCL6 was further shown to bind multiple sites in the BCL-X L promoter in vitro and repress the BCL-X L promoter activity in 293E cells. However, we did not observe any significant effect of BCL6 overexpression on BCL-X L protein levels in Daudi and Raji cells (unpublished observation). Furthermore, we did not observe any endogenous BCL2 expression in these cells, which is in accordance with the fact that germinal center B cells do not generally express BCL2 (Shaffer et al., 2001) . Thus, it is speculated that BCL6 overexpression in heterologous cells may have different cellular effects by repressing physiologically irrelevant genes.
In accordance with the present study showing the antiapoptotic effect of BCL6, we previously demonstrated that BCL6 expression is upregulated during differentiation of myocytes and that adenovirusmediated overexpression of BCL6 prevented apoptosis during myocyte differentiation (Kumagai et al., 1999) . In addition, a recent study in Bcl6-deficient mice suggested a role for BCL6 in protecting apoptosis of spermatocytes, which normally express BCL6, in response to stresses (Kojima et al., 2001) . Furthermore, Shaffer et al. (2000) reported that inhibition of BCL6 function in Raji cells by a dominant-negative form of BCL6, consisting solely of the DNA-binding zinc-finger domain, inhibited the cell cycle progression and induced apoptosis. Together, these observations strongly suggest that BCL6 plays an antiapoptotic role in various types of cells endogenously expressing BCL6, including germinal center B cells and lymphoma cells derived from these cells.
In the present study, an increase in the production of ROS and a decline in Dc m were observed in Daudi and Raji cells treated with etoposide. Furthermore, inhibition of increase in ROS by the antioxidant NAC significantly reduced apoptosis as well as reduction in Dc m , thus suggesting that an increase in the production of ROS may play an important role in etoposideinduced apoptosis in lymphoma cells. In accordance with this, previous studies have demonstrated that ROS act upstream of mitochondrial membrane depolarization and execution of apoptosis by activation of caspases (reviewed in Fleury et al. (2002) , Jabs (1999) ). An early increase in ROS levels preceding mitochondrial membrane permeabilization has also been reported in Cells were then subjected to the flow cytometric analysis for ROS generation using HE Antiapoptotic effect of BCL6 in lymphoma cells T Kurosu et al various models, including apoptosis induced by etoposide (Fleury et al., 2002) . However, previous studies also suggest that reduction of Dc m , concomitant with uncoupling of mitochondrial electron transfer and ATP synthesis, causes increased generation of ROS. Thus, a dual role has been implicated for ROS in the apoptotic process: first, as a facultative signal during the induction phase, and, second, as a common consequence of mitochondrial permeability transition leading to the final destruction of the cell (Jabs, 1999; Fleury et al., 2002) . We speculate that a fraction of Raji cells that showed dramatic increases in ROS levels at 48 h after etoposide treatment may be due to excessive generation of ROS caused by loss of Dc m . In accordance with this speculation, this fraction was significantly smaller or was barely detectable in Raji-BCL6 or Raji-BCL6-Ala333/343 cells, respectively, thus showing a correlation with the fraction of apoptotic cells. More importantly, the early increase in ROS levels after etoposide treatment was also reduced in Raji cells overexpressing BCL6 or its mutant and correlated with their susceptibility to etoposide-induced apoptosis. Inducible overexpression of BCL6 in Daudi cells also reduced the increase in ROS levels in response to etoposide as well as other chemotherapeutic reagents and mitigated apoptosis. Therefore, it is speculated that BCL6 overexpression prevents apoptosis of lymphoma cells in response to chemotherapeutic reagents by inhibiting the increase in ROS levels. Intriguingly, our preliminary data show that BCL6 overexpression also inhibits apoptosis of Daudi and Raji cells cultured under fetal calf serum (FCS)-deprived conditions (unpublished observations), which raises the possibility that the deregulated expression of BCL6 in B cells may play a role in lymphomagenesis through its antiapoptotic effects on various stresses. Currently, studies are also underway in our laboratory to determine the effects of BCL6 on the antioxidant defense systems as well as on the defense systems for mitochondrial integrity. The present study has also revealed that the level of BCL6 declines rapidly in lymphoma cells treated with etoposide or other chemotherapeutic reagents ( Figures  2-4 and data not shown). This is most likely caused by the proteasome-mediated degradation, because it was prevented by the proteasome inhibitors, MG132 and lactacystin, but not by the broad-spectrum caspase inhibitor Z-VAD-fmk ( Figure 5 ). However, it is also possible that the decline in BCL6 level is partly caused at the transcriptional level, because the level of overexpressed BCL6 declined more gradually than that of endogenous BCL6 (Figures 3 and 4) . Notably, the level of BCL6-Ala333/343 did not decline, but transiently increased in cells treated with etoposide in repeated experiments, which may explain the observation that Raji-BCL6-Ala333/343 cells were more resistant to etoposide than Raji-BCL6 cells (Figure 3 and data not shown). It is also speculated that Ser333 and Ser343 of BCL6, sites involved in phosphorylation by Erks and degradation mediated by the proteasome in B-cell receptor signaling (Niu et al., 1998) , may also be involved in proteasome-dependent degradation of BCL6 in cells undergoing apoptosis. Intriguingly, our preliminary results have shown that Erks are activated in Raji cells in response to etoposide, although PD98059, an MEK inhibitor, did not show any significant effect on etoposide-induced BCL6 degradation (unpublished data). Further studies are also underway to elucidate the mechanisms for BCL6 degradation and its significance in the regulation of apoptosis induced by chemotherapeutic reagents.
The results of the present study predict that patients with non-Hodgkin lymphoma with deregulated expression of BCL6 may have poor clinical outcomes, because BCL6 overexpression significantly affected apoptosis of lymphoma cells treated with chemotherapeutic reagents. However, the prognostic significance of BCL6 gene rearrangements or BCL6 expression in DLBCL has remained very controversial, and many contradictory results have so far been reported (Lossos et al., 2001; Barrans et al., 2002; Dent et al., 2002; Niu, 2002) . This may be at least partly caused by the heterogeneity of DLBCL. In particular, a recent gene expression profiling study with DNA microarray techniques has classified DLBCL into two molecularly distinct forms: germinal center B-like and activated B-like forms (Alizadeh et al., 2000) . Germinal center B-like DLBCL is characterized by the expression of genes normally expressed in germinal center B cells, including the BCL6 gene, and is associated with better overall survival. Accordingly, a recent study has defined the BCL6 gene expression as a favorable prognostic factor in DLBCL, although the expression levels of BCL6 protein were not examined (Lossos et al., 2001) . However, in a more recent study, the BCL6 gene rearrangements were more frequently observed in cases not expressing the germinal center Bcell phenotype and were associated with a poor prognosis as revealed by multivariate analysis of a pure cohort of nodal DLBCL (Barrans et al., 2002) . Therefore, it is speculated that the deregulated expression of BCL6, but not its expression per se, predicts a poor clinical outcome in DLBCL. Furthermore, a very recent study has demonstrated that BCL6 is inactivated by acetylation and showed that BCL6 is acetylated under physiologic conditions in normal germinal center B cells and in germinal center-derived B-cell lymphoma cells (Bereshchenko et al., 2002) . Therefore, future studies examining the expression level and acetylation status of BCL6 protein in lymphoma cells may shed more light on the prognostic significance of BCL6 expression and its effect on sensitivities of lymphoma cells to chemotherapeutic reagents. Future studies aiming to exploit BCL6 in lymphoma cells as a molecular target for therapy, for instance by using inhibitors for deacetylases, are also needed (Bereshchenko et al., 2002) .
Materials and methods
Cells and reagents
Burkitt's lymphoma cells lines, Daudi and Raji, were obtained from the Japanese Cancer Resources Bank (JCRB, Tokyo, Japan). Daudi and Raji cells were cultured in RPMI1640 medium (Nissui, Tokyo, Japan) supplemented with 20% or 10% FCS, respectively. 293 T cells were kindly provided by Dr S Yamaoka and cultured in DMEM with 10% FCS. DOX, vincristine, daunorubicin, cytosine arabinoside (Ara-C), MG132 and NAC were purchased from Sigma (St Louis, MO, USA). Etoposide, G418, and hygromycin B were purchased from Wako (Osaka, Japan). Z-VAD-fmk and lactacystin were obtained from Calbiochem (La Jolla, CA, USA). A rabbit polyclonal antibody against BCL6 was described previously (Nakamura, 2000) . A mouse monoclonal antibody against a-tubulin (B-7) was purchased from Sigma, and a rabbit polyclonal antibody against PARP was obtained from New England Biolabs (Beverly, MA, USA).
Construction of expression plasmids
Point mutations causing substitution of both Ser333 and Ser343 with alanine residues were introduced into a full-length human BCL6 cDNA (Miki et al., 1994) by PCR-based methods, as described previously (Niu et al., 1998) , and confirmed by sequencing. The sequences encoding for the Flag tag were added upstream and in frame with sequences coding for wild-type or mutant BCL6 by PCR-based methods and confirmed by sequencing. Subsequently, the wild-type and mutant BCL6 cDNA clones were subcloned into the pCAGGS expression plasmid, kindly provided by Dr J Miyazaki, to give pCAGGS-BCL6 and pCAGGS-BCL6-Ala333/343, respectively. The wild-type BCL6 cDNA clone was also subcloned into pRevTRE (Clontech) to give pRevTRE-BCL6.
Cell transfection and infection
Daudi cells were first transfected with pTet-On (Clontech) by electroporation using Gene Pulser (Bio-Rad, Hercules, CA, USA) at 330V and 960 mF. Transfected cells were selected in medium containing G418 and clones were selected by limiting dilution. One selected clone, Daudi/Ton, was used for control experiments and for infection with a retrovirus carrying the wildtype BCL6 cDNA clone, which was prepared by transfecting 293 T cells with pRevTRE-BCL6, SV-c À -e À , and pHCMV-G (Yee et al., 1994) , kindly provided by Dr J Burns and Dr T Friedmann, by using FuGene6 (Roche) according to the manufacturer's instructions. After 48 h of infection, cells were selected in a medium containing G418 and hygromycin B. Several clones were isolated by limiting dilution and examined for the induction of BCL6 expression by the addition of DOX, and one clone, Daudi/Ton-BCL6, was used for subsequent experiments.
Raji cells were transfected with pCAGGS-BCL6 or pCAGGS-BCL6-Ala333/343 and pSV2neo (Clontech) by electroporation, as described above. Selected clones were examined for BCL6 expression, and the clones expressing the highest level of wild-type or mutant BCL6, Raji-BCL6 and Raji-BCL6-Ala333/343, respectively, were used for subsequent experiments.
Immunoblotting
Cells were lysed in a lysis buffer containing 1% Triton X-100, 20 mm Tris-HCl (pH 7.5), 150 mm NaCl, 1 mm EDTA, 1 mm sodium orthovanadate, 1 mm phenylmethylsulfonyl fluoride, and 10 mg/ml each of aprotinin and leupeptin. For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 2 Â Laemmli's sample buffer and heating at 1001C. Samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and electrotransferred to Immobilon P membrane (Millipore, Bedford, MA, USA). The membranes were probed with a relevant antibody followed by detection using enhanced chemiluminescence Western blotting detection system (Amersham Pharmacia Biotech). For reprobing of the membranes, the membranes were treated with stripping buffer composed of 100 mm 2-mercaptoethanol, 2% SDS, and subsequently probed with a different antibody.
Cell viability assay
Cell viability was measured by the sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) colorimetric assay using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. In brief, cells were cultured in a 96-well dish at a density of 5 Â 10 4 cells per each well in a final volume of 100 ml with indicated concentrations of a chemotherapeutic reagent and cultured for 24 h. Then, 50 ml of XTT labeling mixture was added, and cells were further incubated for 4 h before the optical density at 490 nm was measured with a microplate reader.
Flow cytometric analysis of apoptosis, ROS production and Dc m
For flow cytometric analysis of apoptosis, phosphatidylserine exposure on the outer leaflet of the plasma membrane was detected using the TACS Annexin V Kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. In brief, 1 Â 10 6 cells were resuspended in 100 ml of binding buffer containing annexin V-FITC and propidium iodide (PI) and incubated for 15 min. After 400 ml of binding buffer was added, the cells were analysed using a Becton Dickinson FACSscan flow cytometer (Mountain View, CA, USA).
The production of ROS was estimated fluorometrically using a fluorescent probe, dihydroethidium (HE; Molecular probes, Eugene, OR, USA), which is oxidized to the fluorescent intercalator, ethidium, by cellular oxidants, particularly superoxide radicals (Rothe and Valet, 1990) , as described previously (Dvorakova et al., 2001) . In brief, 1 Â 10 6 cells were incubated with 2 mm HE for 30 min at 371C, resuspended in PBS, and analysed by flow cytometry (excitation: 488 nm, emission: 620 nm).
The Dc m was estimated by using the DePsipher kit (Trevigen), according to the manufacturer's instructions. In brief, 1 Â 10 6 cells were incubated with a lipophilic cation (5, 5 0 , 6, 6 0 , tetrachloro-1, 1 0 , 3, 3 0 -tetraethylbenzimidazolyl carbocyanin iodide) for 20 min at 371C, washed in PBS and analysed by flow cytometry.
